Key facts
- Alpenglow Biosciences’s last known valuation is $14.6M (Jun 2021).
- It has raised $9.8M across 1 recorded rounds; the latest was Seed Round ($3.0M) in Mar 2024.
- Notable investors include Creative Destruction Lab, National Institutes of Health, Mayo Clinic, WRF Capital, Alexandria Real Estate Equities — 12 tracked in total.
- Alpenglow Biosciences has filed 1 Form D with the SEC, most recently Mar 2024 ($1.8M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Alpenglow Biosciences
Funding rounds
1 roundsAbout Alpenglow Biosciences
Developer of a microscopy imaging system designed to analyze images of complex and morphological structures of tissue samples. The company's system leverages proprietary three-dimensional scanning microscopes and artificial intelligence (AI) algorithms to provide spatial biology insights with proprietary sample preparation, light-sheet microscopy, cloud-based data processing and storage, three-dimensional (3D) visualization and AI analysis, enabling healthcare companies to accelerate drug development and improve clinical diagnostics.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2018
- Employees
- 29
- Website
- alpenglowbiosciences.com/
- Ownership
- Privately Held (backing)
Alpenglow Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alpenglow Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alpenglow Biosciences in its N-PORT filings yet. We sweep new filings monthly.